Immunogenicity of a meningococcal serogroup C conjugate vaccine in HIV-infected children, adolescents, and young adults

Vaccine

Volumn 30, Issue 37, 2012, Pages 5482-5486

  Bertolini, Daniela Vinhas ^a   Costa, Luciana Scarlazzari ^b   van der Heijden, Inneke Marie ^c   Sato, Helena Keiko ^c,d   de Sousa Marques, Heloísa Helena ^c  

^a Centro de Referencia e Treinamento em DST AIDS   (Brazil)

^b FEDERAL UNIVERSITY OF THE STATE OF RIO DE JANEIRO   (Brazil)

^c UNIVERSITY OF SÃO PAULO   (Brazil)

^d Secretaria de Estado da Saude de Sao Paulo   (Brazil)

Author keywords

Adolescents; Children; HIV; Immunization; Meningococcal vaccine

Indexed keywords

ANTIRETROVIRUS AGENT; MENINGOCOCCUS VACCINE;

ADOLESCENT; ADOLESCENT DISEASE; ADULT; ADULT DISEASE; ANTIBODY RESPONSE; ARTICLE; CHILD; CHILDHOOD DISEASE; CONTROLLED STUDY; DRUG EFFICACY; DRUG FEVER; DRUG SAFETY; ENZYME LINKED IMMUNOSORBENT ASSAY; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNIZATION; IMMUNOGENICITY; MAJOR CLINICAL STUDY; MENINGOCOCCOSIS; MYALGIA; PAIN; PRIORITY JOURNAL; PROSPECTIVE STUDY; SCHOOL CHILD; SERUM BACTERICIDAL ANTIBODY ASSAY; UNSPECIFIED SIDE EFFECT;

ADOLESCENT; ANTIBODIES, BACTERIAL; CHILD; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HIV INFECTIONS; HUMANS; IMMUNIZATION SCHEDULE; IMMUNIZATION, SECONDARY; MALE; MENINGITIS, MENINGOCOCCAL; MENINGOCOCCAL VACCINES; YOUNG ADULT;

EID: 84864319734     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2012.06.069     Document Type: Article

References (39)

1. Rosenberg Z.F., Fauci A.S. Immunopathology and pathogenesis of HIV infection. Pediatric AIDS: the challenge of HIV infection in infants, children, and adolescents 1994, 115-127. Williams & Wilkins, Baltimore. 2nd ed. P.A. Pizzo, C.M. Wilfert (Eds.).
2. Marques A., Masur H. Manifestações Clínicas da Aids. Tratado de Infectologia 2002, 99-121. Editora Atheneu, São Paulo. 2nd ed. R. Veronesi, R. Focaccia (Eds.).
3. Rachid M., Schechter M. Manifestações clínicas. Manual de HIV/AIDS 2005, 7-12. Editora Revinter, Rio de Janeiro. 8th ed. M. Rachid, M. Schechter (Eds.).
4. Stephens D.S., Hajjeh R.A., Baughman W.S., et al. Sporadic meningococcal disease in adults: results of a 5-year population-based study. Ann Intern Med 1995, 123(12):937-940.
5. Cohen C., Singh E., Wu H.M., et al. Increased incidence of meningococcal disease in HIV-infected individuals associated with higher case-fatality ratios in South Africa. AIDS 2010, 24(9):1351-1360.
6. Obaro S.K., Pugatch D., Luzuriaga K. Immunogenicity and efficacy of childhood vaccines in HIV-1-infected children. Lancet Infect Dis 2004, 4(August (8)):510-518.
7. Moss W.J., Clements C.J., Halsey N.A. Immunization of children at risk of infection with human immunodeficiency virus. Bull World Health Organ 2003, 81(1):61-70.
8. Comitê Assessor em Terapia Antirretroviral em Crianças e Adolescentes Infectados pelo HIV: Ministério da Saúde do Brasil. Recomendações para Terapia Antiretroviral em crianças e adolescentes infectados pelo HIV 2009-Suplemento I. Brasília: Ministério da Saúde do Brasil, Secretaria de Vigilância em Saúde, Departamento de DST, Aids e Hepatites Virais; 2010.
9. Coordenação de Imunizações e Auto-Suficiência em Imunobiológicos. Manual dos Centros de Referência para Imunobiológicos Especiais. Brasília: Ministério da Saúde do Brasil, Secretaria de Vigilância à Saúde, Programa Nacional de Imunizações; 2006.
10. Centers for Disease Control and Prevention (CDC), MMWR. Guidelines for the Prevention and Treatment of Opportunistic Infections among HIV-Exposed and HIV-Infected Children. August 26, 2009/58(Early Release);1-166. Available at: http://AIDSinfo.nih.gov.(last accessed 06.26.11).
11. Sáfadi M.A., Barros A.P. Vacinas meningocócicas conjugadas: eficácia e novas combinações. J Pediatr 2006, 82(3 Suppl.):S35-S44.
12. Borrow R., Miller E. Long-term protection in children with meningococcal C conjugate vaccination: lessons learned. Expert Rev Vaccines 2006, 5(6):851-857.
13. Larrauri A., Cano R., Garcia M., et al. Impact and effectiveness of meningococcal C conjugate vaccine following its introduction in Spain. Vaccine 2005, 23:4097-4100.
14. Balmer P., Falconer M., McDonald P., et al. Immune response to meningococcal serogroup C conjugate vaccine in asplenic individuals. Infection and Immunity 2004, 72(1):332-337.
15. Yu J.W., Borkowski A., Danzig L., et al. Immune response to conjugated meningococcal C vaccine in pediatric oncology patients. Pediatr Blood Cancer 2007, 49:918-923.
16. Zonneveld-Huijssoon E., Ronaghy A., Rossum M., et al. Safety and efficacy of meningococcal c vaccination in juvenile idiopatic arthritis. Arthritis Rheum 2007, 56(2):639-646.
17. Collins C.L., Ruggeberg J.U., Balfour G., et al. Immunogenicity and immunologic memory of meningococcal C conjugate vaccine in premature infants. Pediatr Infect Dis J 2005, 24(11):966-968.
18. Stoehr G.A., Luecken J., Zielen S., et al. Mode of splenectomy and immunogenicity of meningococcal vaccination in patients with hereditary spherocytosis. Br J Surg 2008, 95:466-471.
19. Siberry G.K., Williams P.L., Lujan-Zilbermann J., et al. Phase I/II, open-label trial of safety and immunogenicity of meningococcal (Groups A,C,Y and W-135) polysaccharide diphtheria toxoid conjugate vaccine in human immunodeficiency virus-infected adolescents. Pediatr Infect Dis J 2010, 29(5):391-396.
20. Browner W.S., Newman T.B., Cummings S.R., et al. Estimating sample size and power: the nitty-gritty. Designing clinical research 1998, 65-91. Willians&Wilkins, Baltimore. 2nd ed. S.B. Hulley, S.R. Cummings (Eds.).
21. Sposito AC, Caramelli B, Fonseca FA, et al. IV Diretriz Brasileira sobre Dislipidemias e Prevenção de Aterosclerose. São Paulo: Departamento de Aterosclerose da Sociedade Brasileira de Cardiologia; 2007.
22. Goldschneider I., Gotschlich E.C., Artenstein M.S. Human immunity to the meningococcus, I: the role of humoral antibodies. J Exp Med 1969, 129:1307-1326.
23. Maslanka S.E., Gheesling L.L., De Libutti K.B., et al. Standardization and a multilaboratory comparison of Neisseria meningitidis serogroup A and C serum bactericidal assays. The multilaboratory study group. Clin Diagn Lab Immunol 1997, 4(2):156-167.
24. Gheesling L.L., Carlone G.M., Pais L.B., et al. Multicenter comparison of Neisseria meningitidis serogroup C anti-capsular polysaccharide antibody levels measured by a standardized enzyme-linked immunosorbent assay. J Clin Microbiol 1994, 32(6):1475-1482.
25. Holder P.K., Maslanka S.E., Pais L.B., et al. Assignment of Neisseria meningitidis serogroup A and C class-specific anticapsular antibody concentrations to the new standard reference serum CDC1992. Clin Diagn Lab Immunol 1995, 2(2):132-137.
26. Snape M.D., Pollard A.J. Meningococcal polysaccharide-protein conjugate vaccines. Lancet Infect Dis 2005, 5:21-30.
27. Granoff D.M., Feavers I.M., Borrow R. Meningococcal vaccines. Vaccines 2004, 959-988. Elsevier, Philadelphia. 4th ed. S. Ploktin, W.A. Orenstein (Eds.).
28. Borrow R., Andrews N., Goldblatt D., et al. Serological basis for use of meningococcal serogroup C conjugate vaccines in the United Kingdom: reevaluation of correlates of protection. Infect Immun 2001, 69:1568-1573.
29. Andrews N., Borrow R., Miller E. Validation of serological correlate of protection for meningococcal conjugated vaccine by using efficacy estimates from postlicensure surveillance in England. Clin Diagn Lab Immunol 2003, 10:780-786.
30. Centers for Disease Control and Prevention (CDC), MMWR.Prevention and Control of Meningococcal Disease: Recommendations of the Advisory Committee on Immunization Practices (ACIP). May 27, 2005/54 (n(RR-7). Available at: (last accessed 06.27.11). http://www.cdc.gov/mmwr/pdf/rr/rr5407.pdf.
31. Makela P.H., Kayhty H., Weckstrom P., et al. Effect of group-A meningococcal vaccine in army recruits in Finland. Lancet 1975, 2:883-886.
32. Peltola H., Makela P.H., Kayhty H., et al. Clinical efficacy of meningococcus group A capsular polysaccharide vaccine in children three months to five years of age. N Engl J Med 1977, 297:686-691.
33. Holder P.K., Maslanka S.E., Pais L.B., et al. Assignment of Neisseria meningitidis serogroup A and C class-specific anticapsular antibody concentration to the new standard reference serum CDC1992. Clin Diagn Lab Immunol 1995, 2(2):132-137.
34. Vermont C., Dobbelsteen G. Neisseria meningitidis serogroup B: laboratory correlates of protection. FEMS Immunol Med Microbiol 2002, 34:89-96.
35. Danzig L. Meningococcal vaccines. Pediatr Infect Dis J 2004, 23(12 Suppl.):S285-S292.
36. Gasparini R., Rizzetto R., Sasso T., et al. Seroprevalence of bactericidal antibody against Neisseria meningitidis serogroup C in pre-vaccinal era: the Italian epidemiological scenario. Vaccine 2009, 27:3435-3438.
37. Choo S., Zuckerman J., Goilav C., et al. Immunogenicity and reactogenicity of a group C meningococcal conjugate vaccine compared with a group A+C meningococcal polysaccharide vaccine in adolescents in a randomised observer-blind controlled trial. Vaccine 2000, 18:2686-2692.
38. Snape M.D., Kelly D.F., Lewis S., et al. Seroprotection against serogroup C meningococcal disease in adolescents in United Kingdom: observational study. BMJ 2008, 336:1487-1491.
39. Meningococcal conjugate vaccines policy update: booster dose recommendations. Pediatrics 2011, 128:1213-1218. Committee on Infectious Diseases- American Academy of Pediatrics.